Discovery of LYA914, An Orally Bioavailable PROTAC Degrader Targeting the DNA Binding Domain of the Androgen Receptor for the Treatment of CRPC
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c01463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yan Lv und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, …. Hauptthemen laut MEDLINE: Receptors, Androgen, Prostatic Neoplasms, Castration-Resistant, Antineoplastic Agents, Drug Discovery. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Key Technology Research and Development Program of Shandong Province, Science Fund for Distinguished Young Scholars of Shandong Province, Ocean University of China.
Abstract (Originalsprache)
Prostate cancer is a common male malignancy. Although androgen deprivation therapy (ADT) is initially effective, it often leads to castration-resistant prostate cancer (CRPC) eventually. Second-generation androgen antagonists are the standard therapy for CRPC. However, resistance develops due to mutations or splice variants in the ligand binding domain (LBD) of the androgen receptor (AR). Therefore, the development of novel, efficient, and safe therapeutic agents for CRPC is of great significance. In this study, we designed and synthesized compound LYA914 as a proteolysis-targeting chimera (PROTAC) degrader targeting the conserved DNA binding domain (DBD) of AR, which can simultaneously degrade AR and its variant AR-V7. It demonstrated effective antiproliferative effects in enzalutamide-insensitive/resistant cells. In a VCaP castrated tumor cell model, oral administration of LYA914 obviously inhibited tumor growth, demonstrating superior efficacy compared to enzalutamide. These findings underscore the promising potential of LYA914 for the treatment of CRPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.
- Center for Targeted Protein Degradation and Drug Discovery, Ocean University of China, Qingdao, Shandong 266003, China.
- Laboratory for Marine Drugs and Bioproducts, Pilot National Laboratory for Marine Science and Technology, Qingdao, Shandong 266237, China.
ORCID-Profile: Chong Qin
Förderung
- Key Technology Research and Development Program of Shandong Province
- Science Fund for Distinguished Young Scholars of Shandong Province
- Ocean University of China
- Taishan Scholar Project of Shandong Province
- Qingdao National Laboratory for Marine Science and Technology
- National Key Research and Development Program of China
- Qingdao Key Technology Research and Industrialization Demonstration Projects
Zitieren
APA
Lv, Y., Dai, G., Zhang, B., Liu, C., Chen, Y., Ge, L., Zhang, S., Zhang, S., Ma, M., Ma, S., & Qin, C. (2025). Discovery of LYA914, An Orally Bioavailable PROTAC Degrader Targeting the DNA Binding Domain of the Androgen Receptor for the Treatment of CRPC. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01463
Vancouver
Lv Y, Dai G, Zhang B, Liu C, Chen Y, Ge L, et al. Discovery of LYA914, An Orally Bioavailable PROTAC Degrader Targeting the DNA Binding Domain of the Androgen Receptor for the Treatment of CRPC. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01463
BibTeX
@article{Lv2025,
author = {Lv, Yan and Dai, Gaoxin and Zhang, Bowen and Liu, Chang and Chen, Yiming and Ge, Ling and Zhang, Sai and Zhang, Siqi and Ma, Mengjun and Ma, Shumin and Qin, Chong},
title = {Discovery of LYA914, An Orally Bioavailable PROTAC Degrader Targeting the DNA Binding Domain of the Androgen Receptor for the Treatment of CRPC},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c01463}
}
EUVIMED